1. Home
  2. ENTX vs HNNA Comparison

ENTX vs HNNA Comparison

Compare ENTX & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • HNNA
  • Stock Information
  • Founded
  • ENTX 2010
  • HNNA 1989
  • Country
  • ENTX Israel
  • HNNA United States
  • Employees
  • ENTX 21
  • HNNA N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • HNNA Investment Managers
  • Sector
  • ENTX Health Care
  • HNNA Finance
  • Exchange
  • ENTX Nasdaq
  • HNNA Nasdaq
  • Market Cap
  • ENTX 82.2M
  • HNNA 87.1M
  • IPO Year
  • ENTX 2018
  • HNNA N/A
  • Fundamental
  • Price
  • ENTX $1.85
  • HNNA $11.78
  • Analyst Decision
  • ENTX Strong Buy
  • HNNA
  • Analyst Count
  • ENTX 1
  • HNNA 0
  • Target Price
  • ENTX $10.00
  • HNNA N/A
  • AVG Volume (30 Days)
  • ENTX 76.7K
  • HNNA 9.3K
  • Earning Date
  • ENTX 11-07-2025
  • HNNA 08-06-2025
  • Dividend Yield
  • ENTX N/A
  • HNNA 4.75%
  • EPS Growth
  • ENTX N/A
  • HNNA 56.56
  • EPS
  • ENTX N/A
  • HNNA 1.25
  • Revenue
  • ENTX $166,000.00
  • HNNA $35,816,000.00
  • Revenue This Year
  • ENTX N/A
  • HNNA N/A
  • Revenue Next Year
  • ENTX N/A
  • HNNA N/A
  • P/E Ratio
  • ENTX N/A
  • HNNA $9.28
  • Revenue Growth
  • ENTX 191.23
  • HNNA 32.04
  • 52 Week Low
  • ENTX $1.50
  • HNNA $8.43
  • 52 Week High
  • ENTX $2.79
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 42.76
  • HNNA 50.82
  • Support Level
  • ENTX $1.83
  • HNNA $11.56
  • Resistance Level
  • ENTX $2.22
  • HNNA $12.25
  • Average True Range (ATR)
  • ENTX 0.11
  • HNNA 0.59
  • MACD
  • ENTX -0.02
  • HNNA 0.02
  • Stochastic Oscillator
  • ENTX 9.52
  • HNNA 42.18

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: